drugset
drugset / Trial / NCT05834244

A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)

NCT05834244 ↗

Phase 1 Recruiting 32 enrolled M.D. Anderson Cancer Center
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To learn if adding a healthy person's natural killer (NK) cells to the combination of Azacitidine and Venetoclax can help to control AML. NK cells are cancer- and infection-fighting immune cells.

Timeline

Start
2023-10-26
Primary completion
2028-06-30
Completion
2028-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Azacitidine Other / unclassified — Intravenous
Subject TROCULEUCEL Cell therapy — Intravenous
Subject Venetoclax Small molecule — Oral

Indications

acute myeloid leukemia